Short Interest in Aptose Biosciences Inc. (NASDAQ:APTO) Rises By 13.1%

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) saw a significant growth in short interest in May. As of May 31st, there was short interest totalling 77,000 shares, a growth of 13.1% from the May 15th total of 68,100 shares. Based on an average daily volume of 66,200 shares, the days-to-cover ratio is currently 1.2 days. Approximately 0.5% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of Aptose Biosciences in a report on Friday. Piper Sandler reiterated an “overweight” rating and issued a $5.00 target price on shares of Aptose Biosciences in a report on Wednesday, April 3rd. StockNews.com initiated coverage on shares of Aptose Biosciences in a research report on Friday. They issued a “hold” rating for the company. Finally, Canaccord Genuity Group cut their target price on Aptose Biosciences from $15.00 to $6.00 and set a “buy” rating on the stock in a research note on Thursday, May 16th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, Aptose Biosciences has a consensus rating of “Moderate Buy” and an average target price of $14.83.

Aptose Biosciences Stock Up 2.3 %

Shares of Aptose Biosciences stock traded up $0.02 on Tuesday, reaching $0.89. 12,422 shares of the company traded hands, compared to its average volume of 80,629. The company has a 50 day moving average of $1.15 and a 200 day moving average of $1.71. Aptose Biosciences has a 52 week low of $0.85 and a 52 week high of $5.86.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last released its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.09. As a group, equities analysts predict that Aptose Biosciences will post -2.67 EPS for the current year.

Institutional Investors Weigh In On Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Annandale Capital LLC raised its holdings in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 40.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 74,666 shares of the biotechnology company’s stock after purchasing an additional 21,334 shares during the period. Annandale Capital LLC owned 0.99% of Aptose Biosciences worth $209,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 26.62% of the company’s stock.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.